APA (7th ed.) Citation

Rompoti, N., Stefanaki, I., Panagakis, P., Papoutsaki, M., Politou, M., Vavouli, C., . . . Nicolaidou, E. (2025). Real‐world effectiveness, drug survival and safety of risankizumab over a period of 2 years in 158 patients with moderate‐to‐severe plaque psoriasis. Journal of the European Academy of Dermatology and Venereology, 39(1), e1-e4. https://doi.org/10.1111/jdv.19956

Chicago Style (17th ed.) Citation

Rompoti, Natalia, et al. "Real‐world Effectiveness, Drug Survival and Safety of Risankizumab over a Period of 2 years in 158 Patients with Moderate‐to‐severe Plaque Psoriasis." Journal of the European Academy of Dermatology and Venereology 39, no. 1 (2025): e1-e4. https://doi.org/10.1111/jdv.19956.

MLA (9th ed.) Citation

Rompoti, Natalia, et al. "Real‐world Effectiveness, Drug Survival and Safety of Risankizumab over a Period of 2 years in 158 Patients with Moderate‐to‐severe Plaque Psoriasis." Journal of the European Academy of Dermatology and Venereology, vol. 39, no. 1, 2025, pp. e1-e4, https://doi.org/10.1111/jdv.19956.